HOME >> MEDICINE >> NEWS
FDA approves EPZICOM

Research Triangle Park, NC August 2, 2004 - EPZICOMTM, a new product combining two HIV medicines into one tablet dosed once a day (QD) with no food or fluid requirements, was cleared for prescription use today by the U.S. Food and Drug Administration (FDA). EPZICOM combines two widely-used nucleoside reverse transcriptase inhibitors (NRTIs), EPIVIR(R) (lamivudine, 3TC) and ZIAGEN(R) (abacavir sulfate, ABC) for use in combination with other antiretroviral drugs. The brand name, EPZICOM, is an acronym for EPIVIR and ZIAGEN in COMbination. EPZICOM Tablets are recommended for use in combination with antiretroviral drugs from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors.

GlaxoSmithKline (GSK), manufacturer of EPZICOM, announced today that it is initiating a voucher program for EPZICOM that will provide a 60 day supply of EPZICOM directly to patients at no cost. These vouchers will be available in limited supply through participating healthcare providers for a limited time. Vouchers can be used to initiate antiretroviral therapy for therapy-nave patients or for therapy-experienced patients who require a change in regimen.

"EPZICOM marks an important advance in GSK's ongoing commitment to provide new options in antiretroviral therapy for HIV patients," said Doug Manion, vice president for HIV Clinical Research for the Infectious Diseases Medicines Development Center (MDC) for GSK. "The voucher program will be particularly beneficial to people who are not covered by private health care plans or in specific states where the drug is not yet available on all formularies."

Dr. Manion added that EPZICOM provides patients and treaters with a flexible and potent dosing option that combines two NRTIs that have been widely used in antiretroviral therapy for years. "Prescribers are familiar with these medications, which have an established resistance and long-term safety p
'"/>

Contact: Annie Noland
anoland@pcipr.com
Public Communications Inc.
2-Aug-2004


Page: 1 2 3 4 5

Related medicine news :

1. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain
2. FDA approves Enablex for treatment of overactive bladder
3. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
4. FDA approves Adderall XR (R) to treat ADHD in adults
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves EPZICOM

(Date:12/17/2014)... NY (PRWEB) December 17, 2014 Project ... who recently brought videos of MIT economist and Obamacare ... best-selling author James O’Keefe conducted the interview, which is ... stated that there was intentional mislabeling in the Affordable ... in the bill: A two-hundred-and-fifty billion dollar per year ...
(Date:12/17/2014)... 2014 (HealthDay News) -- Greater participation in music classes ... Researchers followed kids in the nonprofit Harmony Project, ... in Los Angeles. Over two years, children who ... how the brain processes speech and reading, compared to ... benefits of active participation in music classes occurred in ...
(Date:12/15/2014)... Cancer researchers have just published an important new report ... pleural mesothelioma. Surviving Mesothelioma has just posted an article ... to read it now. , Doctors at Harvard, ... York’s Langone Medical Center performed complete genetic analyses on ... effort to pinpoint the genes that are most likely ...
(Date:12/15/2014)... OutMarket , a provider of ... Media Cheat Sheets ,” a guide that exposes the ... on the top ten social media networks. , ... awareness, engagement, and customer service. It can also increase ... impact on new networks and weather constantly changing algorithms, ...
(Date:12/15/2014)... Kathy McAfee, America's Marketing Motivator, was announced a ... category of Best Blog 2014. McAfee received the top ... blog Networking Ahead which combines many different ... talent and influence through better networking, leadership and communication ... Ahead for Business, has been motivating readers for the ...
Breaking Medicine News(10 mins):Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Music Classes Boost Language Skills, Study Says 2Health News:New Study Reveals Genetic Mutations That May Trigger Mesothelioma, According to Surviving Mesothelioma 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... BERGEN, Norway , December 15, 2014 ... developing innovative drugs for aggressive drug resistant cancers, today ... million) in a private placing from new and existing ... the financing to support the development of its pipeline ... development program for its lead drug candidate, BGB324, a ...
(Date:12/15/2014)... PLYMOUTH MEETING, Pa. , Dec. 15, 2014 ... ) announced today it has been added to ... the NASDAQ Biotechnology Index will become effective upon ... The NASDAQ Biotechnology Index is designed to track ... that are classified as either biotechnology or pharmaceutical ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
Cached News: